|
S-3304 in Treating Patients With Advanced Solid Tumors Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on S-3304 in Treating Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. S-3304 in Treating Patients With Advanced Solid Tumors Clinical research trials and S-3304 in Treating Patients With Advanced Solid Tumors health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like S-3304 in Treating Patients With Advanced Solid Tumors. S-3304 in Treating Patients With Advanced Solid Tumors Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a S-3304 in Treating Patients With Advanced Solid Tumors clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their S-3304 in Treating Patients With Advanced Solid Tumors condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > S-3304 in Treating Patients With Advanced Solid Tumors  S-3304 in Treating Patients With Advanced Solid Tumors
S-3304 in Treating Patients With Advanced Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific
Status: No longer recruiting
Sponsor(s): Roswell Park Cancer Institute , National Cancer Institute (NCI)
Synopsis: RATIONALE: S-3304 may stop or slow the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of S-3304 in treating patients who have solid tumors.
Details: OBJECTIVES: - Determine the maximum tolerated dose and safety profile of S-3304 in patients with advanced solid tumors. - Determine the pharmacokinetic profile of this drug in these patients. - Estimate the starting dose of this drug for subsequent phase II efficacy studies. OUTLINE: This is a dose-escalation, multicenter study. Patients receive oral S-3304 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 6-8 patients receive escalating doses of S-3304 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose-limiting toxicity. Patients are followed at 30 days. PROJECTED ACCRUAL: A total of 6-28 patients will be accrued for this study within 1 year.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed solid tumor that failed to respond or relapsed after prior therapy or for which no standard therapy exists - Biopsy-accessible lesion - No brain metastasis unless clinically stable and off therapy PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - More than 6 weeks Hematopoietic: - Absolute neutrophil count greater than 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 9.0 g/dL Hepatic: - Bilirubin no greater than 2 times upper limit of normal (ULN) - Transaminases less than 2.5 times ULN Renal: - Creatinine less than 2.0 mg/dL Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 30 days after study - Able to tolerate oral medication - HIV negative - No AIDS - No serious underlying gastrointestinal disorders (e.g., recurrent vomiting or inflammatory bowel disease) - No other serious concurrent illness PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior immunotherapy - Concurrent stable doses of epoetin alfa are allowed during the second and subsequent courses - No other concurrent immunotherapy Chemotherapy: - At least 4 weeks since prior chemotherapy - No concurrent chemotherapy Endocrine therapy: - At least 4 weeks since prior hormonal therapy - Concurrent stable doses of steroids for prostate cancer are allowed during the second and subsequent courses - No concurrent hormonal therapy Radiotherapy: - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery: - No prior significant gastric resection Other: - Recovered from prior therapy - At least 4 weeks since other prior investigational antitumor drugs - No other concurrent investigational antitumor drugs - Concurrent stable doses of bisphosphonates, cyclo-oxygenase-2 inhibitors, and non-steroidal anti-inflammatory drugs are allowed during the second and subsequent study courses
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PatrickCreaven, Study Chair, Roswell Park Cancer Institute
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
United States
Additional Information:
Study ID Numbers: CDR0000069301; SHIONOGI-0110P1416,RPCI-DS-0120,NCI-G02-2058
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00033566
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors
2. Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
3. Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy
4. PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
5. Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other New York Clinical Trials
Other Buffalo Clinical Trials
S-3304 in Treating Patients With Advanced Solid Tumors
|
|
|
|
|
|
|
|
